Protagonist Therapeutics Inc Working Capital to Net Assets Ratio
Protagonist Therapeutics Inc working capital to net assets ratio. Protagonist Therapeutics Inc (PTGX) has a Working Capital to Net Assets ratio of 83.9% as of September 2025. Working capital of $541.48 Million (current assets of $586.42 Million minus current liabilities of $44.94 Million) is measured against net assets of $645.44 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check PTGX goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Protagonist Therapeutics Inc (2014–2024)
Working capital to net assets ratio of Protagonist Therapeutics Inc from 2014 to 2024. This chart shows how Protagonist Therapeutics Inc's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2014 to 2024. As of September 2025, the ratio stands at 83.9%, reflecting working capital of $541.48 Million against net assets of $645.44 Million USD. See operational self-sufficiency of Protagonist Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Protagonist Therapeutics Inc Working Capital to Net Assets Ratio by Year (2014–2024)
Protagonist Therapeutics Inc working capital to net assets ratio by year from 2014 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Protagonist Therapeutics Inc from 2014 to 2024, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Protagonist Therapeutics Inc total assets.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 80.6% | $544.24 Million | $675.29 Million | $591.64 Million | $47.40 Million | ▼ -18.7 pp |
| 2023 | 99.3% | $334.30 Million | $336.68 Million | $355.58 Million | $21.27 Million | ▲ +1.0 pp |
| 2022 | 98.3% | $211.90 Million | $215.61 Million | $243.08 Million | $31.18 Million | ▼ -0.6 pp |
| 2021 | 98.9% | $296.72 Million | $300.02 Million | $340.74 Million | $44.02 Million | ▲ +0.4 pp |
| 2020 | 98.5% | $275.37 Million | $279.61 Million | $315.61 Million | $40.24 Million | ▼ -39.0 pp |
| 2019 | 137.4% | $109.91 Million | $79.96 Million | $145.31 Million | $35.41 Million | ▲ +38.5 pp |
| 2018 | 99.0% | $111.34 Million | $112.52 Million | $137.50 Million | $26.16 Million | ▲ +9.1 pp |
| 2017 | 89.9% | $108.39 Million | $120.63 Million | $150.95 Million | $42.55 Million | ▲ +2.1 pp |
| 2016 | 87.7% | $76.81 Million | $87.56 Million | $83.24 Million | $6.43 Million | ▼ -27.7 pp |
| 2015 | 115.5% | $11.08 Million | $9.60 Million | $14.21 Million | $3.13 Million | ▲ +7.8 pp |
| 2014 | 107.6% | $8.56 Million | $7.96 Million | $9.91 Million | $1.35 Million | — |